Given the direct link between the pericoronary fat expression of SGLT2 and over-inflammation, it has been shown that reducing the pericoronary fat levels through metformin therapy led to the amelioration of clinical outcomes and improved the clinical outcomes of pre-diabetes patients [86]. The gene discussed is SLC5A2; the disease is diabetes mellitus.